BC Extra | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
Clinical Results | Apr 20, 2018
Clinical Results

ImmuPharma's lupus candidate misses in Phase III

ImmuPharma plc (LSE:IMM) said lead product Lupuzor (forigerimod, P140) missed the primary endpoint in a Phase III trial to treat systemic lupus erythematosus (SLE). The company said it will review the trial's full data set...
BC Extra | Apr 17, 2018
Clinical News

ImmuPharma plummets after Phase III lupus miss

ImmuPharma plc (LSE:IMM) lost 112.70p (77%) to 34.30p on Tuesday after it said lead product Lupuzor (forigerimod, P140) missed the primary endpoint in a Phase III trial to treat systemic lupus erythematosus (SLE). The company...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jan 5, 2017
Clinical News

Lupuzor: Completed Ph III enrollment

ImmuPharma completed enrollment of 200 patients in a double-blind, placebo-controlled, international Phase III trial evaluating 200 ug subcutaneous Lupuzor every 4 weeks plus standard of care (SOC) for 48 weeks. ImmuPharma plc (LSE:IMM), London, U.K. ...
BC Week In Review | Feb 8, 2016
Financial News

ImmuPharma completes placing

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2016-02-05   Type: Placing   Raised: L3.9 million ($5.5 million)   Shares: 14.9 million   Price: 26p   Shares after offering: 121.4...
BC Week In Review | Feb 8, 2016
Financial News

ImmuPharma completes private placement

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2016-02-05   Type: Private placement   Raised: L4.4 million ($6.3 million)   Shares: 17.9 million   Price: 26p   Shares after offering:...
BC Week In Review | Aug 3, 2015
Financial News

ImmuPharma completes debt financing

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2015-07-27   Type: Debt financing   Raised: $2 million   Investor: Not disclosed   Note: The financing is a convertible loan. ImmuPharma...
BC Week In Review | Feb 16, 2015
Clinical News

IPP-204106: Phase I/IIa data

A dose-ranging, European Phase I/IIa trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma said it plans to start a Phase II trial of IPP-204106 to treat pancreatic...
Items per page:
1 - 10 of 63
BC Extra | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
Clinical Results | Apr 20, 2018
Clinical Results

ImmuPharma's lupus candidate misses in Phase III

ImmuPharma plc (LSE:IMM) said lead product Lupuzor (forigerimod, P140) missed the primary endpoint in a Phase III trial to treat systemic lupus erythematosus (SLE). The company said it will review the trial's full data set...
BC Extra | Apr 17, 2018
Clinical News

ImmuPharma plummets after Phase III lupus miss

ImmuPharma plc (LSE:IMM) lost 112.70p (77%) to 34.30p on Tuesday after it said lead product Lupuzor (forigerimod, P140) missed the primary endpoint in a Phase III trial to treat systemic lupus erythematosus (SLE). The company...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jan 5, 2017
Clinical News

Lupuzor: Completed Ph III enrollment

ImmuPharma completed enrollment of 200 patients in a double-blind, placebo-controlled, international Phase III trial evaluating 200 ug subcutaneous Lupuzor every 4 weeks plus standard of care (SOC) for 48 weeks. ImmuPharma plc (LSE:IMM), London, U.K. ...
BC Week In Review | Feb 8, 2016
Financial News

ImmuPharma completes placing

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2016-02-05   Type: Placing   Raised: L3.9 million ($5.5 million)   Shares: 14.9 million   Price: 26p   Shares after offering: 121.4...
BC Week In Review | Feb 8, 2016
Financial News

ImmuPharma completes private placement

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2016-02-05   Type: Private placement   Raised: L4.4 million ($6.3 million)   Shares: 17.9 million   Price: 26p   Shares after offering:...
BC Week In Review | Aug 3, 2015
Financial News

ImmuPharma completes debt financing

ImmuPharma plc (LSE:IMM), London, U.K.   Business: Autoimmune, Neurology, Infectious   Date completed: 2015-07-27   Type: Debt financing   Raised: $2 million   Investor: Not disclosed   Note: The financing is a convertible loan. ImmuPharma...
BC Week In Review | Feb 16, 2015
Clinical News

IPP-204106: Phase I/IIa data

A dose-ranging, European Phase I/IIa trial showed that the MTD of IPP-204106 was 9 mg/kg when administered with chondroitin sulfate. ImmuPharma said it plans to start a Phase II trial of IPP-204106 to treat pancreatic...
Items per page:
1 - 10 of 63